Cancer Research 20 February 2026 - 24 May 2026

Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus
····

Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus

Legend Biotech shares are on a four-day losing streak on Nasdaq as the new week begins. Investors are watching for a Sunday evening cancer conference event that could be key for the stock’s direction. Legend Biotech shares ended Friday at $27.16, losing 3.89% on the session. The stock is now trading about 7.5% lower than the previous Friday’s close of $29.37. U.S. markets saw a shortened week due to the Memorial Day holiday. Nasdaq is closed Sundays and trades Monday to Friday, 9:30 a.m. to 4 p.m. ET.
May 31, 2026
NovoCure Stock Still Up Ahead of Cancer Trial Data
····

NovoCure Stock Still Up Ahead of Cancer Trial Data

NovoCure shares climbed 0.3% Friday, closing the week at $17.96, up 2.2% from last Friday. After the bell, the stock fell to $17.71, with moves more volatile as volume dropped. Small move, but the timing stands out. NovoCure shares are holding around 50% higher than where they closed on April 29, right before the cancer device maker posted Q1 numbers and hiked its 2026 revenue forecast.
May 24, 2026
ImmunityBio Stock Sinks 21% After FDA Warning on Anktiva Cancer Claims
···

ImmunityBio Stock Sinks 21% After FDA Warning on Anktiva Cancer Claims

ImmunityBio stock tumbled roughly 21% this day, dragged down after the U.S. Food and Drug Administration accused the company’s TV ad and podcast for Anktiva of making false or misleading claims that breach federal law. Shares hovered around $7.44 late morning, well below the day’s $9.10 open. That’s a tough spot. Back on March 9, ImmunityBio announced the FDA had accepted its resubmitted bid to expand Anktiva’s label to include papillary-only non-muscle invasive bladder cancer, a type still confined to the bladder lining. The agency’s warning this Tuesday noted it had already raised similar marketing concerns, first in 2025, and again in January.
March 24, 2026
Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3
····

Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3

CORAL GABLES, Fla., March 9, 2026, 09:04 EDT Relmada Therapeutics plans to pull in roughly $160 million through a private placement, the company said Monday, after releasing year-long mid-stage trial data backing a move into late-stage development for NDV-01, its investigational bladder cancer drug. The round, oversubscribed and set at $4.75 per share, is expected to close around March 11.
March 9, 2026